GoldenGolden
WuXi AppTec

WuXi AppTec

An international contract research outsourcing provider for pharmaceutical, biotech, and medical device industries

WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver treatments to patients.

Timeline

May 5, 2019
WuXi AppTec acquires Pharmapace, Inc.
2018
WuXi AppTec was founded by Ge Li, John J. Baldwin and Zhaohui Zhang.
March 2016
WuXi AppTec raises a $1,500,000,000 venture round from Ping An Bank.
July 2008
WuXi AppTec raises a $63,000,000 venture round from Warburg Pincus.
February 2007
WuXi AppTec raises a $17,300,000 series C round from Eight Roads Ventures.
July 2005
WuXi AppTec raises a $2,200,000 series A round from Eight Roads Ventures.

Funding rounds

People

Name
Role
LinkedIn

Adam Choe

Employee

Annie Chen

Employee

Ben Becker

Employee

Ben Meyers

Employee

Brian Moloney

Employee

Cheryl Li

Employee

Craig Coburn

Employee

Dan Zubrzycki

Employee

Daniel Schroen, PhD

Employee

David Dalvey

Investor

Eric Altman

Employee

Erica Rabinovich

Employee

Felix Hsu

Employee

Gennady Gololobov

Employee

Jason Kuchar

Employee

Jeffrey Bernstein

Employee

Jennifer J. Gesell

Employee

Jenny Pflughoeft

Employee

Kateryna Gerrans

Employee

Kenan Alsarabi

Employee

Lance Wang

Employee

Lucas Lin

Employee

Megan Rooney

Employee

Michael Huang

Employee

Peng Zhao

Employee

Page 1 of 2

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
May 3, 2021
BioSpace
Zenas BioPharma, a cross-border biopharmaceutical company committed to the development and delivery of immune-based therapies, announced the appointment of Hua Mu, MD, Ph.D. as President and Chief Executive Officer and Acting Chief Medical Officer and Joe Farmer as Chief Business and Administrative Officer.
WuXi AppTec
March 3, 2021
www.prnewswire.com:443
/PRNewswire/ -- WuXi AppTec, ein weltweit führender Anbieter von F&E- und produktionsunterstützenden Dienstleistungen in der pharmazeutischen,...
WuXi AppTec
March 3, 2021
www.prnewswire.com:443
/PRNewswire/ -- WuXi AppTec, un fournisseur mondial de premier plan de services de R&D et d'aide à la fabrication dans les secteurs pharmaceutique,...
WuXi AppTec
December 3, 2020
www.prnewswire.com:443
/PRNewswire/ -- WuXi AppTec, a leading global provider of R&D and manufacturing enabling services in the pharmaceutical, biotechnology and medical device...
Eudora Wang
November 18, 2020
DealStreetAsia
Boyu Capital, Matrix Partners China, Sequoia Capital China, Temasek and WuXi AppTec unit joined the round.
WuXi AppTec
May 5, 2019
www.prnewswire.com:443
SHANGHAI and SAN DIEGO, May 5, 2019 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology...
Chalida Ekvitthayavechnukul
Invalid Date
DealStreetAsia
The round was joined by life science and tech investors Deerfield Management, Baron, Qiming Venture Partners and GV (formerly known as Google Ventures).
Julia Fioretti
Invalid Date
DealStreetAsia
WuXi AppTec, listed in Shanghai, had raised $1 billion in its Hong Kong initial public offering (IPO), valuing the firm at $10.2 billion in a deal that marks one of this year's last big stock offerings in the Asian financial hub.
WuXi AppTec
Invalid Date
www.prnewswire.com:443
SAN DIEGO and SHANGHAI, Dec. 10, 2018 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology...
Crystal Tse
Invalid Date
DealStreetAsia
WuXi AppTec Co., the Shanghai-listed contract medical researcher, has raised $1.01 billion after pricing its Hong Kong first-time share sale above the midpoint of a marketed range, according to people with knowledge of the matter.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.